PPIA and COVID-19: Our previous study has revealed that meplazumab, a humanized anti-CD147 antibody, effectively inhibited pulmonary inflammation caused by SARS-CoV-2 and its alpha and beta variants by eliminating viral entry and suppressing CyPA-mediated cytokine overproduction.9 In the phase II/III clinical trial, meplazumab treatment significantly reduced mortality of COVID-19 patients and increased live discharge without supplemental oxygen, suggesting the improvement of pulmonary function.